

April 23, 2025

The Manager, Listing Department
The National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051
NSE Symbol: PANACEABIO

BSE Limited
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001
BSE Scrip Code: 531349

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Reg: Receipt of an additional Award from UNICEF for supply of bivalent oral polio vaccine (bOPV) worth ~US\$ 5.20 million in Q3 CY2025

Dear Sir/ Madam,

This is in continuation to our earlier letter dated December 24, 2024 intimating about the receipt of the Letter of Award from UNICEF for supply of 115 million doses of its bivalent oral polio vaccine (bOPV) worth ~US\$ 14.95 million (~Rs.127 Crore) in CY2025.

In terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR Regulations”), we are now delighted to inform you that Panacea Biotec Limited (“the Company”) has received an additional Award from UNICEF for supply of 40 million doses of its bivalent oral polio vaccine (bOPV) worth ~US\$ 5.20 million (~Rs.44 Crore) in Q3 CY2025.

The details with respect to the said award in the specified format as per the SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13.07.2023, is annexed herewith as **Annexure A**.

This is for your kind information and record please.

Thanking you,

Sincerely yours,

For Panacea Biotec Limited

Vinod Goel
Group CFO and Head Legal
& Company Secretary

Disclosure of information pursuant to Regulation 30 of the SEBI LODR Regulations read with SEBI circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023

#	Particulars	Details
a.	Name of the entity awarding the order(s) / contract(s)	United Nations International Children's Emergency Fund (UNICEF)
b.	Significant terms and conditions of order(s)/contract(s) awarded in brief	<p>Additional Award for supply of 40 million doses (2 million vials) of bivalent oral polio vaccine (bOPV) by Panacea Biotec Limited in Q3 CY2025.</p> <p>The existing Long Term Arrangement between UNICEF and the Company will be amended accordingly in due course.</p> <p>UNICEF will make each award public by publishing the following information on the UNICEF website:</p> <ul style="list-style-type: none"> • The supplier's name, vaccine(s), duration of award, and total award value, and • awarded prices per supplier per product presentation per year.
c.	Whether order(s) / contract(s) have been awarded by domestic / international entity	International
d.	Nature of order(s) / contract(s)	Supply of bOPV to UNICEF for its requirements as per the orders as may be received from time to time.
e.	Whether domestic or international	International
f.	Time period by which the order(s) / contract(s) is to be executed	Q3 CY2025
g.	Broad consideration or size of the order(s) / contract(s)	~US\$ 5.20 million (~Rs.44 Crore)
h.	Whether the promoter/ promoter group / group companies have any interest in the entity that awarded the order(s) / contract(s)? If yes, nature of interest and details thereof	No
i.	Whether the order(s) / contract(s) would fall within related party transactions? If yes, whether the same is done at "arm's length"	No

This is for your kind information and record please.

Thanking you,

Sincerely yours,

For **Panacea Biotec Limited**

Vinod Goel

Group CFO and Head Legal & Company Secretary